目的评估自动化磁珠法提取血清脂溶性维生素应用液相色谱串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)检测的性能。方法收集200例临床剩余血清样本,采用自动化磁珠法提取血清中脂溶性维生素A,D_(2),D_(3),E和K...目的评估自动化磁珠法提取血清脂溶性维生素应用液相色谱串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)检测的性能。方法收集200例临床剩余血清样本,采用自动化磁珠法提取血清中脂溶性维生素A,D_(2),D_(3),E和K;同时联合LC-MS/MS检测脂溶性维生素A,D_(2),D_(3),E和K的线性、定量限、精密度、正确度、携带污染率等性能指标以及基质效应。并比较此方法与传统萃取法检测结果的一致性。结果自动化磁珠法提取脂溶性维生素A,D_(2),D_(3),E和K线性相关系数均>0.99;五种物质的定量限分别为5,0.25,0.25,125和0.025ng/ml;批内精密度和批间精密度分别为0.66%~4.83%,0.15%~3.70%;平均加标回收率为87.05%~111.11%;基质效应为95.43%~99.07%;高-低值样本循环进样结果均值与低-低值样本循环进样结果均值之差,均小于低-低值样本循环进样结果均值的3s;统计学结果显示自动化磁珠法和传统萃取法提取的脂溶性维生素结果相关性良好(r>0.99),两种方法的检测结果无显著偏倚。结论自动化磁珠法提取脂溶性维生素的检测性能良好,有望提高样品通量和分析效率。展开更多
基于食品基质中松仁过敏原Pin k 2建立了一种超高效液相色谱-串联质谱法。将松仁经过研磨、脱脂、浸提、酶解后经Easy-nLC 1000-QExactive高分辨质谱仪进行分离分析,结合Uniprot蛋白数据库以及ProteinPilotTM软件对质谱图进行数据处理,...基于食品基质中松仁过敏原Pin k 2建立了一种超高效液相色谱-串联质谱法。将松仁经过研磨、脱脂、浸提、酶解后经Easy-nLC 1000-QExactive高分辨质谱仪进行分离分析,结合Uniprot蛋白数据库以及ProteinPilotTM软件对质谱图进行数据处理,经BLAST验证特异性,最终筛选3条松仁特异性肽段。方法学验证结果表明,方法在0.001~50mg/mL范围内线性关系良好,定量限为1mg/kg;在饼干、巧克力和饮料3种空白基质中的平均回收率为88.50%~107.57%,相对标准偏差不高于6.08%,基质效应为89.77%~96.13%。该方法具有灵敏度高、特异性好的优势,可应用于饼干、巧克力、饮料等食品样品中松仁过敏原的检测,为我国食品标签真实性检验及食品中隐性过敏原的检测提供技术支持。展开更多
建立基于前处理技术结合液相色谱-串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)对鲤鱼基质中苦参碱和氧化苦参碱残留量测定的分析方法.样品采用乙腈均质提取的萃取方式,用硫酸钠作为除水剂,样品经过C18色谱柱...建立基于前处理技术结合液相色谱-串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)对鲤鱼基质中苦参碱和氧化苦参碱残留量测定的分析方法.样品采用乙腈均质提取的萃取方式,用硫酸钠作为除水剂,样品经过C18色谱柱分离,以水-乙腈为流动相,基质匹配标准曲线外标法定量.苦参碱和氧化苦参碱在质量浓度范围1—50 ng·mL^(−1)内,具有良好的线性关系,相关系数R^(2)均大于0.99.苦参碱方法检出限为0.21 ng·mL^(−1),定量限为0.69 ng·mL^(−1);氧化苦参碱方法检出限为0.17 ng·mL^(−1),定量限为0.52 ng·mL^(−1).添加浓度水平1.0、2.0、5.0 ng·mL^(−1),平均回收率为72.5%—108.7%,相对标准偏差(relative standard deviation,RSD,n=6)为4.2%—8.2%.苦参碱和氧化苦参碱的基质效应均表现为抑制.该方法前处理方法简单,灵敏度高,稳定性好,适合鲤鱼基质苦参碱和氧化苦参碱残留量的测定,同时为后续同类样品检测提供参考,也为今后相关标准制定提供数据积累.展开更多
The spread of tuberculosis(TB),especially multidrug-resistant TB and extensively drug-resistant TB,has strongly motivated the research and development of new anti-TB drugs.New strategies to facilitate drug combination...The spread of tuberculosis(TB),especially multidrug-resistant TB and extensively drug-resistant TB,has strongly motivated the research and development of new anti-TB drugs.New strategies to facilitate drug combinations,including pharmacokinetics-guided dose optimization and toxicology studies of first-and second-line anti-TB drugs have also been introduced and recommended.Liquid chromatography-mass spectrometry(LC-MS)has arguably become the gold standard in the analysis of both endo-and exo-genous compounds.This technique has been applied successfully not only for therapeutic drug monitoring(TDM)but also for pharmacometabolomics analysis.TDM improves the effectiveness of treatment,reduces adverse drug reactions,and the likelihood of drug resistance development in TB patients by determining dosage regimens that produce concentrations within the therapeutic target window.Based on TDM,the dose would be optimized individually to achieve favorable outcomes.Pharmacometabolomics is essential in generating and validating hypotheses regarding the metabolism of anti-TB drugs,aiding in the discovery of potential biomarkers for TB diagnostics,treatment monitoring,and outcome evaluation.This article highlighted the current progresses in TDM of anti-TB drugs based on LC-MS bioassay in the last two decades.Besides,we discussed the advantages and disadvantages of this technique in practical use.The pressing need for non-invasive sampling approaches and stability studies of anti-TB drugs was highlighted.Lastly,we provided perspectives on the prospects of combining LC-MS-based TDM and pharmacometabolomics with other advanced strategies(pharmacometrics,drug and vaccine developments,machine learning/artificial intelligence,among others)to encapsulate in an all-inclusive approach to improve treatment outcomes of TB patients.展开更多
文摘目的评估自动化磁珠法提取血清脂溶性维生素应用液相色谱串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)检测的性能。方法收集200例临床剩余血清样本,采用自动化磁珠法提取血清中脂溶性维生素A,D_(2),D_(3),E和K;同时联合LC-MS/MS检测脂溶性维生素A,D_(2),D_(3),E和K的线性、定量限、精密度、正确度、携带污染率等性能指标以及基质效应。并比较此方法与传统萃取法检测结果的一致性。结果自动化磁珠法提取脂溶性维生素A,D_(2),D_(3),E和K线性相关系数均>0.99;五种物质的定量限分别为5,0.25,0.25,125和0.025ng/ml;批内精密度和批间精密度分别为0.66%~4.83%,0.15%~3.70%;平均加标回收率为87.05%~111.11%;基质效应为95.43%~99.07%;高-低值样本循环进样结果均值与低-低值样本循环进样结果均值之差,均小于低-低值样本循环进样结果均值的3s;统计学结果显示自动化磁珠法和传统萃取法提取的脂溶性维生素结果相关性良好(r>0.99),两种方法的检测结果无显著偏倚。结论自动化磁珠法提取脂溶性维生素的检测性能良好,有望提高样品通量和分析效率。
文摘基于食品基质中松仁过敏原Pin k 2建立了一种超高效液相色谱-串联质谱法。将松仁经过研磨、脱脂、浸提、酶解后经Easy-nLC 1000-QExactive高分辨质谱仪进行分离分析,结合Uniprot蛋白数据库以及ProteinPilotTM软件对质谱图进行数据处理,经BLAST验证特异性,最终筛选3条松仁特异性肽段。方法学验证结果表明,方法在0.001~50mg/mL范围内线性关系良好,定量限为1mg/kg;在饼干、巧克力和饮料3种空白基质中的平均回收率为88.50%~107.57%,相对标准偏差不高于6.08%,基质效应为89.77%~96.13%。该方法具有灵敏度高、特异性好的优势,可应用于饼干、巧克力、饮料等食品样品中松仁过敏原的检测,为我国食品标签真实性检验及食品中隐性过敏原的检测提供技术支持。
基金sponsored by the National Research Foundation of Korea(NRF)Grant funded by the Korean government(MSIT)(Grant No.:2018R1A5A2021242).
文摘The spread of tuberculosis(TB),especially multidrug-resistant TB and extensively drug-resistant TB,has strongly motivated the research and development of new anti-TB drugs.New strategies to facilitate drug combinations,including pharmacokinetics-guided dose optimization and toxicology studies of first-and second-line anti-TB drugs have also been introduced and recommended.Liquid chromatography-mass spectrometry(LC-MS)has arguably become the gold standard in the analysis of both endo-and exo-genous compounds.This technique has been applied successfully not only for therapeutic drug monitoring(TDM)but also for pharmacometabolomics analysis.TDM improves the effectiveness of treatment,reduces adverse drug reactions,and the likelihood of drug resistance development in TB patients by determining dosage regimens that produce concentrations within the therapeutic target window.Based on TDM,the dose would be optimized individually to achieve favorable outcomes.Pharmacometabolomics is essential in generating and validating hypotheses regarding the metabolism of anti-TB drugs,aiding in the discovery of potential biomarkers for TB diagnostics,treatment monitoring,and outcome evaluation.This article highlighted the current progresses in TDM of anti-TB drugs based on LC-MS bioassay in the last two decades.Besides,we discussed the advantages and disadvantages of this technique in practical use.The pressing need for non-invasive sampling approaches and stability studies of anti-TB drugs was highlighted.Lastly,we provided perspectives on the prospects of combining LC-MS-based TDM and pharmacometabolomics with other advanced strategies(pharmacometrics,drug and vaccine developments,machine learning/artificial intelligence,among others)to encapsulate in an all-inclusive approach to improve treatment outcomes of TB patients.